EFFICACY, TOLERABILITY, AND SAFETY OF CALCIPOTRIOL OINTMENT IN DISORDERS OF KERATINIZATION - RESULTS OF A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, RIGHT-LEFT COMPARATIVE-STUDY

被引:71
|
作者
KRAGBALLE, K
STEIJLEN, PM
IBSEN, HH
VANDEKERKHOF, PCM
ESMANN, J
SORENSEN, LH
AXELSEN, MB
机构
[1] AARHUS UNIV HOSP,DEPT DERMATOL,DK-8000 AARHUS,DENMARK
[2] UNIV NIJMEGEN HOSP,DEPT DERMATOL,NIJMEGEN,NETHERLANDS
[3] ODENSE UNIV HOSP,DEPT DERMATOL,DK-5000 ODENSE,DENMARK
[4] LEO PHARMACEUT PROD,DK-2750 BALLERUP,DENMARK
关键词
D O I
10.1001/archderm.131.5.556
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Design: Disorders of keratinization are a heterogeneous group of diseases that have in common a defect in cornification. The bioactive form of vitamin D-3 has been shown to modulate epidermal proliferation and differentiation. The purpose of the present study was to determine the effect of the synthetic vitamin D-3 calcipotriol in a randomized, double-blind, placebo-controlled, right/left comparative study. The 67 patients included in the study were at least 12 years of age and had the following diseases: ichthyosis vulgaris (n=9), X-linked ichthyosis (n=8), congenital ichthyosis (n=10), hereditary palmoplantar keratoderma (n=20), keratosis pilaris (n=9), and Darier's disease (n=11). Calcipotriol ointment (SO mu g/g) and placebo (vehicle of calcipotriol ointment) were applied to all patients twice daily for up to 12 weeks. The patients were allowed to use up to 120 g of calcipotriol ointment per week. Results: At the end of the treatment regimen, calcipotriol ointment had an effect on the improvement of the ichthyoses, although to a variable degree. No therapeutic effect was detected in palmoplantar keratoderma or keratosis pilaris. Eight of 12 patients with Darier's disease had to be withdrawn because of skin irritation or a worsening of the disease. Skin irritation occurred in 18 cases (26%) only on the calcipotriol-treated side, and in one case (1%) only on the placebo-treated side. Nine cases (13%) had irritation on both sides. The amount of calcipotriol ointment used per week was lowest in palmoplantar keratoderma (mean, 11.8 g/wk; range, 2.1 to 25.6 g/wk) and highest in congenital ichthyosis (mean, 59.3 g/wk; range, 11.4 to 94.7 g/wk). There was no clinically significant change of serum calcium levels during the treatment period. Conclusion: Short-term treatment with calcipotriol ointment (50 mu g/g) used in amounts up to about 100 g/wk is moderately efficacious, well-tolerated, and safe in adult patients with various ichthyoses.
引用
收藏
页码:556 / 560
页数:5
相关论文
共 50 条
  • [21] Photodamage pilot study: A double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel
    Sefton, J
    Kligman, AM
    Kopper, SC
    Lue, JC
    Gibson, JR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (04) : 656 - 663
  • [22] Efficacy and safety results from a randomized, double-blind, vehicle-controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp
    Cook-Bolden, Fran E.
    Goffe, Bernard S.
    Hudson, Charles P.
    Sofen, Howard L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB140 - AB140
  • [23] EFFICACY AND SAFETY OF PIROXICAM AND INDOMETHACIN IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - DOUBLE-BLIND COMPARATIVE-STUDY
    GUNTHER, R
    EGG, D
    HEROLD, M
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 1979, 38 (9-10): : 330 - 334
  • [24] The Efficacy and Tolerability of Tazarotene Foam, 0.1%, in the Treatment of Acne Vulgaris in 2 Multicenter, Randomized, Vehicle-Controlled, Double-Blind Studies
    Feldman, Steven R.
    Werner, Cary P.
    Saenz, Alessandra B. Alio
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (04) : 438 - 446
  • [25] Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial
    Hashim, Peter W.
    Chima, Margot
    Kim, Hee J.
    Bares, Jennifer
    Yao, Christopher J.
    Singer, Giselle
    Chen, Tinley
    Genece, Jordan
    Baum, Danielle
    Kimmel, Grace W.
    Nia, John K.
    Gagliotti, Matthew
    Lebwohl, Mark G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 360 - 365
  • [26] Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial
    Saeki, Hidehisa
    Ito, Kensuke
    Yokota, Daisuke
    Tsubouchi, Hidetsugu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (03) : 607 - 614
  • [27] Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: Results of a randomized double-blind study
    Geusen, P
    Alten, R
    Rovensky, J
    Sloan, V
    Krammer, G
    Kralidis, G
    Richardson, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S242 - S242
  • [28] Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial
    Guenther, L
    Cambazard, F
    Van de Kerkhof, PCM
    Snellman, E
    Kragballe, K
    Chu, AC
    Tegner, E
    Garcia-Diez, A
    Springborg, J
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) : 316 - 323
  • [29] A multicenter randomized, vehicle-controlled, double-blind clinical study to examine the safety and efficacy of MAS063DP in the management of AD
    Abramovits, W
    Hebert, A
    Boguniewicz, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB84 - AB84
  • [30] SUBGINGIVAL MINOCYCLINE HYDROCHLORIDE OINTMENT IN MODERATE TO SEVERE CHRONIC ADULT PERIODONTITIS - A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, MULTICENTER STUDY
    VANSTEENBERGHE, D
    BERCY, P
    KOHL, J
    DEBOEVER, J
    ADRIAENS, P
    VANDERFAEILLIE, A
    ADRIAENSSEN, C
    ROMPEN, E
    DEVREE, H
    MCCARTHY, EF
    VANDENHOVEN, G
    JOURNAL OF PERIODONTOLOGY, 1993, 64 (07) : 637 - 644